Kidney Transplant

Despite a significant decrease in immunosuppression, the occurrence of post-COVID-19 donor-specific antibodies among COVID-19-positive kidney transplant recipients was low, according to data published in Kidney International Reports.

A survey of staff in the Southeast of America revealed the COVID-19 pandemic significantly impacted the kidney transplant process, such as referrals and evaluations, according to data published in Kidney International Reports.

From 2010 to 2020, the number of stage 3 AKI kidneys transplanted has increased, according to data published in American Journal of Transplantation.

In a study of kidney transplant patients who showed no immune response to two SARS-CoV-2 vaccines, 39% developed antibodies within 4 weeks of a third dose.

The FDA granted accelerated approval for Calliditas Therapeutics’ drug Tarpeyo, also known as budesonide, making it the first and only FDA-approved treatment for reducing proteinuria in IgA nephropathy, according to a company press release.

Pegloticase decreased serum urate in patients with uncontrolled gout who previously received a kidney transplant and were treated with more than one immunosuppressive therapy to protect against organ rejection.

In this video, Craig A. Shadur, MD, a transplant nephrologist from Des Moines, Iowa, discussed the use of pegloticase for patients with kidney transplants.

Those on dialysis or who have previously received a kidney transplant face a higher risk for COVID-19-related death after infection due to the way the virus amplifies these patients’ already intense immunophenotypic alterations.

Five years after the Kidney Allocation System was implemented, racial and ethnic disparities decreased in pediatric transplantations but the wait time for kidney transplants increased for pediatric patients of all races and ethnicities.

Even with a waitlist close to 100,000 individuals seeking a kidney transplant, approximately 20% of organs procured are discarded each year.